Dr. Rachel Rosovsky, MD, MPH is a board-certified hematologist at Massachusetts General Hospital (MGH) Cancer Center, where she provides clinical care full-time, supervises trainees and conducts research in the area of thrombosis and hemostasis. She is an Assistant Professor of Medicine at Harvard Medical School, Director of Thrombosis Research in Division of Hematology at MGH and Co-Chair of MGH’s Thrombosis Committee. She earned her undergraduate degree from the University of Pennsylvania, her medical degree from Harvard Medical School and her Master‘s in Public Health from Harvard School of Public Health. She completed her residency at Brigham and Women’s Hospital and her fellowship at the Dana Farber Cancer Institute/MGH combined program.
Dr. Rosovsky is on the Board of Directors of the National Pulmonary Embolism Response Team (PERT) Consortium and as part of this enterprise, she also serves as the Associate Chair of the Education Committee. She is on the Executive Committee of MGH PERT and is the creator and director of MGH PERT multidisciplinary follow up clinic. She is on the Medical and Scientific Advisory Board for the National Blood Clot Alliance (NBCA). She is also on the Executive Committee for the Venous thromboEmbolism Network US (VENUS). She serves on the panel for NCCN guidelines for Hematopoietic Growth Factors. She has collaborated locally, nationally and internationally with prominent researchers on the risks, diagnosis and treatment of VTE, and she has presented and published widely in this area. Since the COVID-19 pandemic, she has been actively involved in investigating how COVID-19 and coagulopathy is affecting patients both in her own institution and worldwide; she has published on the rates of VTE and COVID19 and how that correlates with biomarkers such as D-dimer, conducted a global survey of anticoagulation practices among experts from 41 countries, helped create a COVID-19 and PE registry, and most recently, spearheaded the PERT Consortium Position Paper on the Diagnosis and Treatment of Pulmonary Embolism During the COVID-19 Pandemic. Through lecturing, research, and written works, she has sought to improve the care of patients with VTE and advance the understanding and treatment of this medical condition.